# Nurix Therapeutics, Inc.: financial statements, quarterly

NRIX · Nasdaq · CIK 1549595 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Nov 30

Pages: [Overview](/companies/nrix.md) · [Financials](/companies/nrix/financials.md) · [Filings](/companies/nrix/filings.md) · [Insiders](/companies/nrix/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nrix/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.2 d](/filings/0001549595-26-000016.md) | [16.6](/filings/0001549595-25-000055.md) | [12.1](/filings/0001549595-25-000095.md) | [12.6](/filings/0001549595-25-000113.md) | [13.3 d](/filings/0001549595-26-000016.md) | [18.5](/filings/0001549595-26-000025.md) | [44.1](/filings/0001549595-26-000040.md) | [7.9](/filings/0001549595-26-000049.md) | [13.6 d](/filings/0001549595-26-000016.md) | [6.3](/filings/0001549595-26-000025.md) | [9.0](/filings/0001549595-26-000040.md) | [673](/filings/0001549595-26-000049.md) |
| Research and development | $m | [49.7 d](/filings/0001549595-26-000016.md) | [50.0](/filings/0001549595-25-000055.md) | [48.9](/filings/0001549595-25-000095.md) | [55.5](/filings/0001549595-25-000113.md) | [67.2 d](/filings/0001549595-26-000016.md) | [69.7](/filings/0001549595-26-000025.md) | [78.1](/filings/0001549595-26-000040.md) | [86.1](/filings/0001549595-26-000049.md) | [83.0 d](/filings/0001549595-26-000016.md) | [84.1](/filings/0001549595-26-000025.md) | [87.7](/filings/0001549595-26-000040.md) | [79.3](/filings/0001549595-26-000049.md) |
| Operating income | $m | [(45.3) d](/filings/0001549595-26-000016.md) | [(45.2)](/filings/0001549595-25-000055.md) | [(48.5)](/filings/0001549595-25-000095.md) | [(54.6)](/filings/0001549595-25-000113.md) | [(64.7) d](/filings/0001549595-26-000016.md) | [(62.9)](/filings/0001549595-26-000025.md) | [(48.3)](/filings/0001549595-26-000040.md) | [(91.4)](/filings/0001549595-26-000049.md) | [(83.1) d](/filings/0001549595-26-000016.md) | [(92.5)](/filings/0001549595-26-000025.md) | [(94.2)](/filings/0001549595-26-000040.md) | [559](/filings/0001549595-26-000049.md) |
| Income tax | $m | [0.0 d](/filings/0001549595-26-000016.md) | [0.1](/filings/0001549595-25-000055.md) | [0.1](/filings/0001549595-25-000095.md) | [0.1](/filings/0001549595-25-000113.md) | [0.0 d](/filings/0001549595-26-000016.md) | [0.0](/filings/0001549595-26-000025.md) | [0.8](/filings/0001549595-26-000040.md) | [0.0](/filings/0001549595-26-000049.md) | [0.0 d](/filings/0001549595-26-000016.md) | [0.0](/filings/0001549595-26-000025.md) | [(0.3)](/filings/0001549595-26-000040.md) | [13.6](/filings/0001549595-26-000049.md) |
| Net income | $m | [(42.0) d](/filings/0001549595-26-000016.md) | [(41.5)](/filings/0001549595-25-000113.md) | [(44.5)](/filings/0001549595-25-000113.md) | [(49.0)](/filings/0001549595-25-000113.md) | [(58.5) d](/filings/0001549595-26-000016.md) | [(56.4)](/filings/0001549595-26-000049.md) | [(43.5)](/filings/0001549595-26-000049.md) | [(86.4)](/filings/0001549595-26-000049.md) | [(78.2) d](/filings/0001549595-26-000016.md) | [(87.2)](/filings/0001549595-26-000049.md) | [(89.5)](/filings/0001549595-26-000049.md) | [550](/filings/0001549595-26-000049.md) |
| Diluted EPS | $ per share | not reported | [(0.76)](/filings/0001549595-25-000055.md) | [(0.71)](/filings/0001549595-25-000095.md) | [(0.67)](/filings/0001549595-25-000113.md) | not reported | [(0.67)](/filings/0001549595-26-000025.md) | [(0.52)](/filings/0001549595-26-000040.md) | [(1.03)](/filings/0001549595-26-000049.md) | not reported | [(0.79)](/filings/0001549595-26-000025.md) | [(0.81)](/filings/0001549595-26-000040.md) | [4.73](/filings/0001549595-26-000049.md) |
| Basic EPS | $ per share | not reported | [(0.76)](/filings/0001549595-25-000055.md) | [(0.71)](/filings/0001549595-25-000095.md) | [(0.67)](/filings/0001549595-25-000113.md) | not reported | [(0.67)](/filings/0001549595-26-000025.md) | [(0.52)](/filings/0001549595-26-000040.md) | [(1.03)](/filings/0001549595-26-000049.md) | not reported | [(0.79)](/filings/0001549595-26-000025.md) | [(0.81)](/filings/0001549595-26-000040.md) | [4.93](/filings/0001549595-26-000049.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [54.6](/filings/0001549595-26-000016.md) | [49.8](/filings/0001549595-25-000055.md) | [117](/filings/0001549595-25-000095.md) | [99.0](/filings/0001549595-25-000113.md) | [110](/filings/0001549595-26-000016.md) | [75.9](/filings/0001549595-26-000025.md) | [84.3](/filings/0001549595-26-000040.md) | [78.4](/filings/0001549595-26-000049.md) | [247](/filings/0001549595-26-000049.md) | [71.2](/filings/0001549595-26-000025.md) | [67.7](/filings/0001549595-26-000040.md) | [720](/filings/0001549595-26-000049.md) |
| Current assets | $m | [296](/filings/0001549595-25-000016.md) | [251](/filings/0001549595-24-000049.md) | [450](/filings/0001549595-24-000098.md) | [456](/filings/0001549595-24-000131.md) | [619](/filings/0001549595-26-000016.md) | [564](/filings/0001549595-25-000055.md) | [515](/filings/0001549595-25-000095.md) | [441](/filings/0001549595-25-000113.md) | [607](/filings/0001549595-26-000049.md) | [554](/filings/0001549595-26-000025.md) | [456](/filings/0001549595-26-000040.md) | [1,104](/filings/0001549595-26-000049.md) |
| Total assets | $m | [356](/filings/0001549595-25-000016.md) | [313](/filings/0001549595-24-000049.md) | [511](/filings/0001549595-24-000098.md) | [514](/filings/0001549595-24-000131.md) | [669](/filings/0001549595-26-000016.md) | [615](/filings/0001549595-25-000055.md) | [592](/filings/0001549595-25-000095.md) | [522](/filings/0001549595-25-000113.md) | [688](/filings/0001549595-26-000049.md) | [636](/filings/0001549595-26-000025.md) | [536](/filings/0001549595-26-000040.md) | [1,195](/filings/0001549595-26-000049.md) |
| Current liabilities | $m | [87.0](/filings/0001549595-25-000016.md) | [87.6](/filings/0001549595-24-000049.md) | [80.8](/filings/0001549595-24-000098.md) | [86.3](/filings/0001549595-24-000131.md) | [95.9](/filings/0001549595-26-000016.md) | [90.0](/filings/0001549595-25-000055.md) | [75.6](/filings/0001549595-25-000095.md) | [82.4](/filings/0001549595-25-000113.md) | [86.5](/filings/0001549595-26-000049.md) | [92.2](/filings/0001549595-26-000025.md) | [72.0](/filings/0001549595-26-000040.md) | [131](/filings/0001549595-26-000049.md) |
| Total liabilities | $m | [155](/filings/0001549595-25-000016.md) | [144](/filings/0001549595-24-000049.md) | [140](/filings/0001549595-24-000098.md) | [137](/filings/0001549595-24-000131.md) | [142](/filings/0001549595-26-000016.md) | [134](/filings/0001549595-25-000055.md) | [144](/filings/0001549595-25-000095.md) | [150](/filings/0001549595-25-000113.md) | [149](/filings/0001549595-26-000049.md) | [155](/filings/0001549595-26-000025.md) | [133](/filings/0001549595-26-000040.md) | [227](/filings/0001549595-26-000049.md) |
| Shareholders' equity | $m | [200](/filings/0001549595-26-000016.md) | [169](/filings/0001549595-25-000113.md) | [371](/filings/0001549595-25-000113.md) | [377](/filings/0001549595-25-000113.md) | [527](/filings/0001549595-26-000049.md) | [481](/filings/0001549595-26-000049.md) | [448](/filings/0001549595-26-000049.md) | [372](/filings/0001549595-26-000049.md) | [539](/filings/0001549595-26-000049.md) | [481](/filings/0001549595-26-000049.md) | [403](/filings/0001549595-26-000049.md) | [968](/filings/0001549595-26-000049.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [26.7 d](/filings/0001549595-26-000016.md) | [(42.0)](/filings/0001549595-25-000055.md) | [(39.7) d](/filings/0001549595-25-000095.md) | [(42.2) d](/filings/0001549595-25-000113.md) | [(48.8) d](/filings/0001549595-26-000016.md) | [(61.1)](/filings/0001549595-26-000025.md) | [(63.2) d](/filings/0001549595-26-000040.md) | [(57.4) d](/filings/0001549595-26-000049.md) | [(67.8) d](/filings/0001549595-26-000016.md) | [(71.9)](/filings/0001549595-26-000025.md) | [(96.6) d](/filings/0001549595-26-000040.md) | [616 d](/filings/0001549595-26-000049.md) |
| Capital expenditure | $m | [2.6 d](/filings/0001549595-26-000016.md) | [2.9](/filings/0001549595-25-000055.md) | [1.9 d](/filings/0001549595-25-000095.md) | [2.3 d](/filings/0001549595-25-000113.md) | [2.1 d](/filings/0001549595-26-000016.md) | [3.5](/filings/0001549595-26-000025.md) | [2.7 d](/filings/0001549595-26-000040.md) | [2.7 d](/filings/0001549595-26-000049.md) | [5.1 d](/filings/0001549595-26-000016.md) | [1.0](/filings/0001549595-26-000025.md) | [1.9 d](/filings/0001549595-26-000040.md) | [1.4 d](/filings/0001549595-26-000049.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-02-28) | Q2 FY2023 (2023-05-31) | Q3 FY2023 (2023-08-31) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.0](/filings/0001549595-24-000049.md) | [54.3](/filings/0001549595-24-000098.md) | [54.4](/filings/0001549595-24-000131.md) | [54.9](/filings/0001549595-25-000055.md) | [62.4](/filings/0001549595-25-000095.md) | [72.8](/filings/0001549595-25-000113.md) | [83.6](/filings/0001549595-26-000025.md) | [83.9](/filings/0001549595-26-000040.md) | [84.2](/filings/0001549595-26-000049.md) | [110](/filings/0001549595-26-000025.md) | [111](/filings/0001549595-26-000040.md) | [116](/filings/0001549595-26-000049.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 109,249,814 at 2026-09-30, from the cover of the [10-Q filed 2026-10-13](/filings/0001549595-26-000049.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.